Quanticate Announces new Partnership with Antev Ltd
August 25, 2020
Quanticate is pleased to partner with Antev Limited on a Phase II, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a GnRH antagonist, in Participants with Advanced Prostate Cancer.
Prostate cancer is one of the most commonly diagnosed cancers and is a major cause of death in men worldwide. GnRH antagonists act by direct inhibition of GnRH receptors and therefore Luteinizing Hormone to reduce testosterone levels.
Quanticate is a Data Specialist CRO who has extensive experience supporting numerous oncology programs, including in prostate cancer. We are very much looking forward to supporting Antev on this important and crucial study by providing specialist statistics, programming, data management and medical writing solutions.
Quanticate meets the needs of drug‑ and device‑development companies by offering customer‑focused resource solutions from fixed‑cost orfunctional‑service‑provider (FSP) modelsthrough to consultancy. Quanticate has become the trusted supplier of choice for many companies from niche biotechnology and device companies to top tier pharmaceutical giants.
About Antev: Antev is a clinical-stage biopharmaceutical company focused on the development of a robust registration-ready data package in areas of unmet clinical need for men’s health: prostate cancer, benign prostatic hyperplasia (BPH) and acute urinary retention (AUR), and establishing value in women’s health indications: endometriosis and uterine fibroids.